Monogram Technologies INC

Zimmer Biomet Holdings, Inc. has completed its acquisition of Monogram Technologies Inc., integrating Monogram's AI-driven orthopedic robotics into its portfolio.

Monogram Technologies Inc. stockholders approved the merger with Zimmer Biomet Holdings, Inc., moving closer to a second-half 2025 closing.

Monogram Technologies and Zimmer Biomet extended their merger regulatory review by withdrawing and refiling HSR notifications, pushing the waiting period to October 6, 2025.

Monogram Technologies Inc. is urging stockholders to vote on the proposed acquisition by Zimmer Biomet Holdings, Inc. at a special meeting scheduled for September 30, 2025.

Monogram Technologies Inc. and Zimmer Biomet Holdings, Inc. amended their merger agreement to revise the definition of 'Permitted Transfer' in the CVR Agreement following an SEC comment.

Monogram Technologies Inc. has informed its stockholders via text message about the availability of frequently asked questions regarding its proposed acquisition by Zimmer Biomet Holdings, Inc.

Monogram Technologies Inc. announced a definitive merger agreement with Zimmer Biomet Holdings, Inc., offering shareholders $4.04 cash plus contingent value rights per common share.

Monogram Technologies Inc. announces its Q1 2025 financial results, including a net loss of $3.2 million, while also celebrating FDA 510(k) clearance for its mBs TKA System and regulatory approval for a clinical trial in India.

Monogram Technologies reported a net loss of $5.03 million for the third quarter of 2024, while also providing updates on their FDA 510(k) submission and recent capital raising activities.

Monogram Technologies reported a net loss for the second quarter of 2024, while also making progress on its robotic surgery system and securing additional funding.

Monogram Orthopaedics reported a net loss of $3.5 million for Q1 2024, while making progress on its robotic surgical system and preparing for a 510(k) submission.

Monogram Technologies Inc. files its 10-K, detailing 2024 financials and progress on its robotic surgical system, awaiting FDA clearance.

Monogram Orthopaedics' 10-K filing outlines its capital structure, including common and preferred stock details, and anti-takeover provisions.

Monogram Technologies Director Colleen Gray's stock options were cancelled and converted into cash and contingent value rights following the merger with Zimmer Biomet.

Monogram Technologies Inc. Director Colleen Gray acquired 5,000 stock options with an exercise price of $2.50, increasing her total beneficial ownership of derivative securities to 8,000, though the Form 4 was filed significantly late.

Richard Van Kirk's Monogram Technologies stock options were cancelled and converted into cash and CVRs following the merger with Zimmer Biomet.

Monogram Technologies Director Douglas Unis reported the disposition of common stock and stock options following the company's merger with Zimmer Biomet.

Monogram Technologies Chief Technology Officer Kamran Shamaei's shares and options were converted into cash and contingent value rights following the merger with Zimmer Biomet.

Monogram Technologies' CEO, Benjamin Sexson, reported the disposal of common stock and stock options following the company's merger with Zimmer Biomet Holdings, Inc.

Monogram Technologies Inc. is reminding shareholders to vote on the proposed acquisition by Zimmer Biomet Holdings, Inc. and offering guidance on share transfers.

Monogram Technologies Inc. is actively soliciting stockholder votes for the upcoming special meeting on September 30, 2025, to approve its acquisition by Zimmer Biomet Holdings, Inc.

Monogram Technologies Inc. stockholders are invited to a special meeting on September 30, 2025, to vote on a proposed merger with Zimmer Biomet Holdings, Inc., offering $4.04 cash plus contingent value rights per common share.

Monogram Technologies Inc. and Zimmer Biomet Holdings, Inc. amended their merger agreement, specifically modifying the definition of "Permitted Transfer" in the CVR Agreement following an SEC comment.

Monogram Technologies Inc. informed stockholders via text message about updated FAQs regarding its proposed acquisition by Zimmer Biomet Holdings, Inc.

Monogram Technologies Inc. informed shareholders about a new FAQ section on its Investor Relations page providing details on the proposed acquisition by Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc. and its subsidiary, Honey Badger Merger Sub, Inc., have entered into a definitive agreement to acquire Monogram Technologies Inc. for a combination of cash and contingent value rights, valuing common stock at up to $16.41 per share.

Icahn School of Medicine at Mount Sinai has reported a 5.8% beneficial ownership stake in Monogram Technologies Inc., holding 2,360,304 shares as of December 31, 2023.